
Opinion|Videos|March 21, 2025
Navigating the Boxed Warning for the JAK Inhibitor Class
Panelists discuss how clinicians can interpret and apply the JAK inhibitor class boxed warning to make informed treatment decisions while weighing potential risks against therapeutic benefits for individual patients.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
The Weekly Roundup: December 1-5
3
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
4
Experts See Promise in AI for Atopic Dermatitis Care
5
















